Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 10:391:83-88.
doi: 10.1016/j.canlet.2017.01.022. Epub 2017 Jan 24.

Redirecting the focus of cancer immunotherapy to premalignant conditions

Affiliations
Review

Redirecting the focus of cancer immunotherapy to premalignant conditions

M Rita I Young. Cancer Lett. .

Abstract

Much progress has been made in introducing immunological treatment approaches for cancer, with lessons learned from both the successes and failures of immunotherapy. Among the challenges of immunotherapeutic approaches for cancer are the multitudes of mechanisms by which cancers are known to subvert the immune defenses. This has led to the incorporation into the immunotherapeutic arsenal strategies by which to overcome the cancer's immunological blockades. What has been only superficially explored is the immunological milieu of premalignant lesions and the possibility of immunological approaches for the treatment of premalignant lesions so as to prevent secondary premalignant lesions and their progression to cancer. This review discusses the immunological environment associated with premalignant lesions, and the possible missed opportunity of utilizing immunological treatment strategies in the less hostile environment of premalignant lesions as compared to the immune subversive cancer environment.

Keywords: Cancer; Immune infiltrate; Immunotherapy; Premalignant.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

None to declare.

Similar articles

Cited by

References

    1. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–287. - PubMed
    1. Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, et al. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007;13(9):2714–2721. - PubMed
    1. Park T, Choi CJ, Choi Y, Suh DC. Cost-effectiveness of cetuximab for colorectal cancer. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):667–677. - PubMed
    1. Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, et al. NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma. J Neurooncol. 2016 - PMC - PubMed
    1. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers. 2011;3(4):3856–3893. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources